Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria

NCT04402489 is registered in ClinicalTrials.gov with Tanabe Pharma America, Inc. as lead sponsor.

NCT NCT04402489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Lead sponsor
Tanabe Pharma America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2020
Completion date
July 26, 2022
Enrollment
184 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

epp, xlp